Hepatocellular Carcinoma: Epidemiology, Screening, and Assessment of Hepatic Reserve

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2020 Dec 21

PMID 33343207

Citations 20

Authors

S Z Frager

J M Schwartz

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma is a leading cause of cancer-related mortality worldwide. This review summarizes the epidemiology and causes of the disease, and the roles of screening and surveillance for early tumour detection. It also highlights the important role of assessment of hepatic reserve in consideration of appropriate staging and treatment.

Citing Articles

Liquid biopsy kinetics and detection of ERBB2 amplification/HER2-positivity in refractory hepatocellular carcinoma.

Geddam A, Lutfi A, Afghan M, Currie B, Rosenblatt R, Ramirez A J Liq Biopsy. 2025; 2:100009.

PMID: 40028484 PMC: 11863877. DOI: 10.1016/j.jlb.2023.100009.

Decoding the Prognostic Significance and Therapeutic Implications of Inflammation-Based Scores in Hepatocellular Carcinoma: A Comprehensive Review.

Kotsifa E, Machairas N, Angelis A, Nikiteas N, Dimitroulis D, Sotiropoulos G Cancers (Basel). 2024; 16(14).

PMID: 39061188 PMC: 11274930. DOI: 10.3390/cancers16142549.

Real-world treatment patterns, clinical outcomes, and health care resource utilization in advanced unresectable hepatocellular carcinoma.

OSullivan D, Boyne D, Syed I, Shephard C, Clouthier D, Yoshida E Can Liver J. 2023; 5(4):476-492.

PMID: 38144405 PMC: 10735199. DOI: 10.3138/canlivj-2022-0001.

Twelve protections evolved for the brain, and their roles in extending its functional life.

Stone J, Mitrofanis J, Johnstone D, Robinson S Front Neuroanat. 2023; 17:1280275.

PMID: 38020212 PMC: 10657866. DOI: 10.3389/fnana.2023.1280275.

circSLCO1B7 suppresses the malignant progression of hepatocellular carcinoma via the miR-556-3p/DAB2IP axis.

Ju L, Zhou Q, Qi Q, She Y, Cai W, Cao Y Aging (Albany NY). 2023; 15(22):13329-13344.

PMID: 38015711 PMC: 10713434. DOI: 10.18632/aging.205244.

References

Zhang B, Yang B, Tang Z . Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004; 130(7):417-22. DOI: 10.1007/s00432-004-0552-0. View

Bruix J, Reig M, Sherman M . Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016; 150(4):835-53. DOI: 10.1053/j.gastro.2015.12.041. View

McGlynn K, Petrick J, London W . Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015; 19(2):223-38. PMC: 4712629. DOI: 10.1016/j.cld.2015.01.001. View

Baran B . Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World J Hepatol. 2015; 7(13):1742-54. PMC: 4491903. DOI: 10.4254/wjh.v7.i13.1742. View

Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves H . Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2014; 33(6):550-8. PMC: 4322258. DOI: 10.1200/JCO.2014.57.9151. View

Yang J, Hainaut P, Gores G, Amadou A, Plymoth A, Roberts L . A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16(10):589-604. PMC: 6813818. DOI: 10.1038/s41575-019-0186-y. View

Chang M, Chen C, Lai M, Hsu H, Wu T, Kong M . Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997; 336(26):1855-9. DOI: 10.1056/NEJM199706263362602. View

McGlynn K, Petrick J, El-Serag H . Epidemiology of Hepatocellular Carcinoma. Hepatology. 2020; 73 Suppl 1:4-13. PMC: 7577946. DOI: 10.1002/hep.31288. View

Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin C . Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2017; 43(1):13-25. DOI: 10.1007/s00261-017-1209-1. View

10.

Singal A, Pillai A, Tiro J . Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014; 11(4):e1001624. PMC: 3972088. DOI: 10.1371/journal.pmed.1001624. View

11.

De Mitri M, Poussin K, Baccarini P, Pontisso P, DErrico A, Simon N . HCV-associated liver cancer without cirrhosis. Lancet. 1995; 345(8947):413-5. DOI: 10.1016/s0140-6736(95)90400-x. View

12.

Singal A, Lampertico P, Nahon P . Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020; 72(2):250-261. PMC: 6986771. DOI: 10.1016/j.jhep.2019.08.025. View

13.

Kansagara D, Papak J, Pasha A, ONeil M, Freeman M, Relevo R . Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med. 2014; 161(4):261-9. DOI: 10.7326/M14-0558. View

14.

Kanwal F, Kramer J, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson P . Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018; 155(6):1828-1837.e2. PMC: 6279617. DOI: 10.1053/j.gastro.2018.08.024. View

15.

Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T . Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993; 328(25):1797-801. DOI: 10.1056/NEJM199306243282501. View

16.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

17.

Woodard G, Downey J, Hernandez-Boussard T, Morton J . Impaired alcohol metabolism after gastric bypass surgery: a case-crossover trial. J Am Coll Surg. 2010; 212(2):209-14. DOI: 10.1016/j.jamcollsurg.2010.09.020. View

18.

El-Serag H . Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142(6):1264-1273.e1. PMC: 3338949. DOI: 10.1053/j.gastro.2011.12.061. View

19.

Younossi Z, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M . Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015; 62(6):1723-30. DOI: 10.1002/hep.28123. View

20.

Sung J, Tsoi K, Wong V, Li K, Chan H . Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008; 28(9):1067-77. DOI: 10.1111/j.1365-2036.2008.03816.x. View